Cargando…
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity
Anti-CD52 therapy has been shown to be effective in the treatment of a number of B cell malignancies, hematopoietic disorders and autoimmune diseases (including rheumatoid arthritis and multiple sclerosis); however the current standard of treatment, the humanized monoclonal antibody alemtuzumab, is...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570798/ https://www.ncbi.nlm.nih.gov/pubmed/26372145 http://dx.doi.org/10.1371/journal.pone.0138123 |